Loading stock research

Aridis Pharmaceuticals, Inc.

ARDS

HealthcareOTCUS

Sign in to save

$0.0002

$0.00 (+0.00%)

Overview Financials Analysis Valuation Thesis Ownership Compare AI Report News

ARDS News

News and disclosures filtered by period, publisher, and event group.

3 / 3

Filter options

Results

Select a headline to open the full news page in the app.

May 31, 2026, 9:00 AMgurufocus.comARDS

RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) pivotal data show strong and durable responses in advanced head and neck cancer where options remain limited

Security terms

RYBREVANT FASPROâ¢ (amivantamab and hyaluronidase-lpuj) pivotal data show strong and durable responses in advanced head and neck cancer where

May 29, 2026, 3:00 PMgurufocus.comARDS

RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) demonstrates prolonged clinical benefit as a first-line treatment for atypical EGFR-mutated non-small cell lung cancer

Company announcements

RYBREVANTÂ (amivantamab-vmjw) plus LAZCLUZEÂ (lazertinib) demonstrates prolonged clinical benefit as a first-line treatment for atypical EGFR

Mar 31, 2026, 4:20 PMglobenewswire.comARDS

Edesa Biotech Invited for Oral Showcase at Respiratory Innovation Summit

Financial reports

Selection Follows Positive Phase 3 Results for Paridiprubart Demonstrating Statistically Significant Mortality Reductions in ARDS Patients Selection Follows Positive Phase 3 Results for Paridiprubart Demonstrating Statistically Significant Mortality Reductions in ARDS Patients

Loading disclosure news